Obesity and Diabetes pp 233-254

Part of the Contemporary Diabetes book series (CDI) | Cite as

Obesity, Diabetes, and Risk of Cancer

A Review of Epidemiological Studies
  • Susanna C. Larsson
  • Hans-Olov Adami
  • Alicja Wolk


Risk of cancer is affected by a number of environmental and lifestyle factors and by an interplay between these factors and genetic susceptibility. Over the past three decades, the prevalence of obesity and type 2 diabetes has been increasing in both developed countries and less developed areas along with an adoption of a Westernized lifestyle (See Chapter 2). It is well recognized that obesity dramatically increases the risk of type 2 diabetes. Moreover, there is an extensive body of epidemiological evidence that excess body weight considerably increases the risk of cancers at multiple sites (1). Herein we summarize the mounting epidemiological studies linking overweight, obesity, and diabetes with cancer incidence and mortality.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention: Weight Control and Physical Activity. (Vaino, H and Bianchini, F, eds). IARC Press, Lyon, France, 2002.Google Scholar
  2. 2.
    Bergström A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91:421–430.PubMedCrossRefGoogle Scholar
  3. 3.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med 2003;348:1625–1638.PubMedCrossRefGoogle Scholar
  4. 4.
    Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee. World Health Organ 1995;854:1–452.Google Scholar
  5. 5.
    Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13–21.PubMedCrossRefGoogle Scholar
  6. 6.
    Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y. Association of obesity and cancer risk in Canada. Am J Epidemiol 2004;159:259–268.PubMedCrossRefGoogle Scholar
  7. 7.
    Weiderpass E, Gridley G, Nyren O, Pennello G, Landstrom AS, Ekbom A. Cause-specific mortality in a cohort of patients with diabetes mellitus: a population-based study in Sweden. J Clin Epidemiol 2001;54:802–809.PubMedCrossRefGoogle Scholar
  8. 8.
    Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827–841.PubMedCrossRefGoogle Scholar
  9. 9.
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8–29.PubMedGoogle Scholar
  10. 10.
    de Waard F, Baanders-van Halewijn EA. A prospective study in general practice on breast-cancer risk in postmenopausal women. Int J Cancer 1974;14:153–160.PubMedCrossRefGoogle Scholar
  11. 11.
    van den Brandt PA, Spiegelman D, Yaun SS, et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000;152:514–527.PubMedCrossRefGoogle Scholar
  12. 12.
    Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer risk: findings from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 2004;111:762–771.PubMedCrossRefGoogle Scholar
  13. 13.
    Michels KB, Solomon CG, Hu FB, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care 2003;26:1752–1758.PubMedCrossRefGoogle Scholar
  14. 14.
    Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami HO. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 1997;71:360–363.PubMedCrossRefGoogle Scholar
  15. 15.
    Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La Vecchia C. Selected medical conditions and risk of breast cancer. Br J Cancer 1997;75:1699–1703.PubMedGoogle Scholar
  16. 16.
    Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004;159:1160–1167.PubMedCrossRefGoogle Scholar
  17. 17.
    Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360–1365.PubMedCrossRefGoogle Scholar
  18. 18.
    Weiss HA, Brinton LA, Potischman NA, et al. Breast cancer risk in young women and history of selected medical conditions. Int J Epidemiol 1999;28:816–823.PubMedCrossRefGoogle Scholar
  19. 19.
    La Vecchia C, Negri E, Franceschi S, D’Avanzo B, Boyle P. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 1994;70:950–953.PubMedGoogle Scholar
  20. 20.
    Kopp S, Tanneberger S, Mohner M, Kieser R. Diabetes and breast cancer risk. Int J Cancer 1990;46:751, 752.PubMedCrossRefGoogle Scholar
  21. 21.
    Moseson M, Koenig KL, Shore RE, Pasternack BS. The influence of medical conditions associated with hormones on the risk of breast cancer. Int J Epidemiol 1993;22:1000–1009.PubMedCrossRefGoogle Scholar
  22. 22.
    Sellers TA, Sprafka JM, Gapstur SM, et al. Does body fat distribution promote familial aggregation of adult onset diabetes mellitus and postmenopausal breast cancer? Epidemiology 1994;5:102–108.PubMedCrossRefGoogle Scholar
  23. 23.
    Grady D, Ernster V. Endometrial cancer. In: Schottenfeld D, Fraumeni J, eds. Cancer Epidemiology and Prevention, 2nd ed. Oxford University Press, New York, 1996, pp. 1058–1108.Google Scholar
  24. 24.
    Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 2000;11:185–192.PubMedCrossRefGoogle Scholar
  25. 25.
    Parazzini F, La Vecchia C, Negri E, et al. Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer 1999;81:539–542.PubMedCrossRefGoogle Scholar
  26. 26.
    Anderson KE, Anderson E, Mink PJ, et al. Diabetes and endometrial cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev 2001;10:611–616.PubMedGoogle Scholar
  27. 27.
    Salazar-Martinez E, Lazcano-Ponce EC, Lira-Lira GG, et al. Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control 2000;11:707–711.PubMedCrossRefGoogle Scholar
  28. 28.
    Shoff SM, Newcomb PA. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 1998;148:234–240.PubMedGoogle Scholar
  29. 29.
    O’Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 1985;38:435–441.PubMedCrossRefGoogle Scholar
  30. 30.
    Purdie DM, Bain CJ, Webb PM, Whiteman DC, Pirozzo S, Green AC. Body size and ovarian cancer: case-control study and systematic review (Australia). Cancer Causes Control 2001;12:855–863.PubMedCrossRefGoogle Scholar
  31. 31.
    Lubin F, Chetrit A, Freedman LS, et al. Body mass index at age 18 years and during adult life and ovarian cancer risk. Am J Epidemiol 2003;157:113–120.PubMedCrossRefGoogle Scholar
  32. 32.
    Schouten LJ, Goldbohm RA, van den Brandt PA. Height, weight, weight change, and ovarian cancer risk in the Netherlands cohort study on diet and cancer. Am J Epidemiol 2003;157:424–433.PubMedCrossRefGoogle Scholar
  33. 33.
    Farrow DC, Weiss NS, Lyon JL, Daling JR. Association of obesity and ovarian cancer in a case-control study. Am J Epidemiol 1989;129:1300–1304.PubMedGoogle Scholar
  34. 34.
    Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis 1979;32:563–576.PubMedCrossRefGoogle Scholar
  35. 35.
    Garfinkel L. Overweight and cancer. Ann Intern Med 1985;103:1034–1036.PubMedGoogle Scholar
  36. 36.
    Dal Maso L, Franceschi S, Negri E, et al. Body size indices at different ages and epithelial ovarian cancer risk. Eur J Cancer 2002;38:1769–1774.CrossRefGoogle Scholar
  37. 37.
    Fairfield KM, Willett WC, Rosner BA, Manson JE, Speizer FE, Hankinson SE. Obesity, weight gain, and ovarian cancer. Obstet Gynecol 2002;100:288–296.PubMedCrossRefGoogle Scholar
  38. 38.
    Anderson JP, Ross JA, Folsom AR. Anthropometric variables, physical activity, and incidence of ovarian cancer: the Iowa Women’s Health Study. Cancer 2004;100:1515–1521.PubMedCrossRefGoogle Scholar
  39. 39.
    Tornberg SA, Carstensen JM. Relationship between Quetelet’s index and cancer of breast and female genital tract in 47,000 women followed for 25 years. Br J Cancer 1994;69:358–361.PubMedGoogle Scholar
  40. 40.
    Byers T, Marshall J, Graham S, Mettlin C, Swanson M. A case-control study of dietary and nondietary factors in ovarian cancer. J Natl Cancer Inst 1983;71:681–686.PubMedGoogle Scholar
  41. 41.
    Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994;30A:344–350.PubMedCrossRefGoogle Scholar
  42. 42.
    Jonsson F, Wolk A, Pedersen NL, et al. Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish Twin Registry. Int J Cancer 2003;106:594–599.PubMedCrossRefGoogle Scholar
  43. 43.
    Lukanova A, Toniolo P, Lundin E, et al. Body mass index in relation to ovarian cancer: a multi-centre nested case-control study. Int J Cancer 2002;99:603–608.PubMedCrossRefGoogle Scholar
  44. 44.
    Kuper H, Cramer DW, Titus-Ernstoff L. Risk of ovarian cancer in the United States in relation to anthropometric measures: does the association depend on menopausal status? Cancer Causes Control 2002;13:455–463.PubMedCrossRefGoogle Scholar
  45. 45.
    Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst 2003;95:1244–1248.PubMedGoogle Scholar
  46. 46.
    Parazzini F, Moroni S, La Vecchia C, Negri E, dal Pino D, Bolis G. Ovarian cancer risk and history of selected medical conditions linked with female hormones. Eur J Cancer 1997;33:1634–1637.PubMedCrossRefGoogle Scholar
  47. 47.
    Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control 2002;13:759–764.PubMedCrossRefGoogle Scholar
  48. 48.
    Adler AI, Weiss NS, Kamb ML, Lyon JL. Is diabetes mellitus a risk factor for ovarian cancer? A case-control study in Utah and Washington (United States). Cancer Causes Control 1996;7:475–478.PubMedCrossRefGoogle Scholar
  49. 49.
    Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control 1991;2:307–314.PubMedCrossRefGoogle Scholar
  50. 50.
    Kessler II. Cancer mortality among diabetics. J Natl Cancer Inst 1970;44:673–686.PubMedGoogle Scholar
  51. 51.
    Ragozzino M, Melton LJ 3rd, Chu CP, Palumbo PJ. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 1982;35:13–19.PubMedCrossRefGoogle Scholar
  52. 52.
    Smith GD, Egger M, Shipley MJ, Marmot MG. Post-challenge glucose concentration, impaired glucose tolerance, diabetes, and cancer mortality in men. Am J Epidemiol 1992;136:1110–1114.PubMedGoogle Scholar
  53. 53.
    Will JC, Vinicor F, Calle EE. Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 1999;10:313–318.PubMedCrossRefGoogle Scholar
  54. 54.
    Tavani A, Gallus S, Bosetti C, et al. Diabetes and the risk of prostate cancer. Eur J Cancer Prev 2002;11:125–128.PubMedCrossRefGoogle Scholar
  55. 55.
    Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Reduced risk of prostate cancer among patients with diabetes mellitus. Int J Cancer 2002;102:258–261.PubMedCrossRefGoogle Scholar
  56. 56.
    Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States). Cancer Causes Control 1998;9:3–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Coker AL, Sanderson M, Zheng W, Fadden MK. Diabetes mellitus and prostate cancer risk among older men: population-based case-control study. Br J Cancer 2004;90:2171–2175.PubMedGoogle Scholar
  58. 58.
    Zhu K, Lee IM, Sesso HD, Buring JE, Levine RS, Gaziano JM. History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol 2004;159:978–982.PubMedCrossRefGoogle Scholar
  59. 59.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.PubMedCrossRefGoogle Scholar
  60. 60.
    La Vecchia C, D’Avanzo B, Negri E, Franceschi S. History of selected diseases and the risk of colorectal cancer. Eur J Cancer 1991;27:582–586.PubMedCrossRefGoogle Scholar
  61. 61.
    Nilsen TI, Vatten LJ. Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001;84:417–422.PubMedCrossRefGoogle Scholar
  62. 62.
    Will JC, Galuska DA, Vinicor F, Calle EE. Colorectal cancer: another complication of diabetes mellitus? Am J Epidemiol 1998;147:816–825.PubMedGoogle Scholar
  63. 63.
    Hu FB, Manson JE, Liu S, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91:542–547.PubMedCrossRefGoogle Scholar
  64. 64.
    Le Marchand L, Wilkens LR, Kolonel LN, Hankin JH, Lyu LC. Associations of sedentary lifestyle, obesity, smoking, alcohol use, and diabetes with the risk of colorectal cancer. Cancer Res 1997;57:4787–4794.PubMedGoogle Scholar
  65. 65.
    Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988;48:4399–4404.PubMedGoogle Scholar
  66. 66.
    Bergström A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer—a quantitative review. Br J Cancer 2001;85:984–990.PubMedCrossRefGoogle Scholar
  67. 67.
    Lindblad P, Wolk A, Bergstrom R, Persson I, Adami HO. The role of obesity and weight fluctuations in the etiology of renal cell cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 1994;3:631–639.PubMedGoogle Scholar
  68. 68.
    Wynder EL, Mabuchi K, Whitmore WF Jr. Epidemiology of adenocarcinoma of the kidney. J Natl Cancer Inst 1974;53:1619–1634.PubMedGoogle Scholar
  69. 69.
    McLaughlin JK, Gao YT, Gao RN, et al. Risk factors for renal-cell cancer in Shanghai, China. Int J Cancer 1992;52:562–565.PubMedCrossRefGoogle Scholar
  70. 70.
    Asal NR, Geyer JR, Risser DR, Lee ET, Kadamani S, Cherng N. Risk factors in renal cell carcinoma. II. Medical history, occupation, multivariate analysis, and conclusions. Cancer Detect Prev 1988;13:263–279.PubMedGoogle Scholar
  71. 71.
    McCredie M, Stewart JH. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control 1992;3:323–331.PubMedCrossRefGoogle Scholar
  72. 72.
    Schlehofer B, Pommer W, Mellemgaard A, et al. International renal-cell-cancer study. VI. The role of medical and family history. Int J Cancer 1996;66:723–726.PubMedCrossRefGoogle Scholar
  73. 73.
    Mellemgaard A, Niwa S, Mehl ES, Engholm G, McLaughlin JK, Olsen JH. Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol 1994;23: 923–930.PubMedCrossRefGoogle Scholar
  74. 74.
    Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control 1993;4:101–110.PubMedCrossRefGoogle Scholar
  75. 75.
    Goodman MT, Morgenstern H, Wynder EL. A case-control study of factors affecting the development of renal cell cancer. Am J Epidemiol 1986;124:926–941.PubMedGoogle Scholar
  76. 76.
    Lindblad P, Chow WH, Chan J, et al. The role of diabetes mellitus in the aetiology of renal cell cancer. Diabetologia 1999;42:107–112.PubMedCrossRefGoogle Scholar
  77. 77.
    Coughlin SS, Neaton JD, Randall B, Sengupta A. Predictors of mortality from kidney cancer in 332,547 men screened for the Multiple Risk Factor Intervention Trial. Cancer 1997;79:2171–2177.PubMedCrossRefGoogle Scholar
  78. 78.
    Berrington de Gonzalez A, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 2003;89:519–523.CrossRefGoogle Scholar
  79. 79.
    Coughlin SS, Calle EE, Patel AV, Thun MJ. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000;11:915–923.PubMedCrossRefGoogle Scholar
  80. 80.
    Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000;283:2552–2558.PubMedCrossRefGoogle Scholar
  81. 81.
    Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS. Physical activity, obesity, height, and the risk of pancreatic cancer. JAMA 2001;286:921–929.PubMedCrossRefGoogle Scholar
  82. 82.
    Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis. JAMA 1995;273:1605–1609.PubMedCrossRefGoogle Scholar
  83. 83.
    Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CW Jr. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 1998;9:403–410.PubMedCrossRefGoogle Scholar
  84. 84.
    Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18–29.PubMedCrossRefGoogle Scholar
  85. 85.
    Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049–53.PubMedCrossRefGoogle Scholar
  86. 86.
    Blot WJ, Devesa SS, Fraumeni JF Jr. Continuing climb in rates of esophageal adenocarcinoma: an update. JAMA 1993;270:1320.PubMedCrossRefGoogle Scholar
  87. 87.
    Hansson LE, Sparen P, Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer 1993;54:402–407.PubMedCrossRefGoogle Scholar
  88. 88.
    Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85–92.PubMedGoogle Scholar
  89. 89.
    Brown LM, Swanson CA, Gridley G, et al. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995;87:104–109.PubMedCrossRefGoogle Scholar
  90. 90.
    Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150–155.PubMedCrossRefGoogle Scholar
  91. 91.
    Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883–890.PubMedGoogle Scholar
  92. 92.
    Cheng KK, Sharp L, McKinney PA, et al. A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer 2000;83:127–132.PubMedCrossRefGoogle Scholar
  93. 93.
    Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes Control 2001;12:721–732.PubMedCrossRefGoogle Scholar
  94. 94.
    Ji BT, Chow WH, Yang G, et al. Body mass index and the risk of cancers of the gastric cardia and distal stomach in Shanghai, China. Cancer Epidemiol Biomarkers Prev 1997;6:481–485.PubMedGoogle Scholar
  95. 95.
    Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. J Natl Cancer Inst 2003;95:1404–1413.PubMedGoogle Scholar
  96. 96.
    Kritchevsky D. Caloric restriction and experimental carcinogenesis. Toxicol Sci 1999;52:13–16.PubMedGoogle Scholar
  97. 97.
    Liao DJ, Dickson RB. Roles of androgens in the development, growth, and carcinogenesis of the mammary gland. J Steroid Biochem Mol Biol 2002;80:175–189.PubMedCrossRefGoogle Scholar
  98. 98.
    Dickson RB, Thompson EW, Lippman ME. Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids. J Steroid Biochem Mol Biol 1990;37:305–316.PubMedCrossRefGoogle Scholar
  99. 99.
    Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472–1489.PubMedCrossRefGoogle Scholar
  100. 100.
    Kaaks R, Lukanova A. Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 2001;60:91–106.PubMedCrossRefGoogle Scholar
  101. 101.
    Nestler JE. Obesity, insulin, sex steroids and ovulation. Int J Obes Relat Metab Disord 2000;24(Suppl 2):S71–S73.PubMedGoogle Scholar
  102. 102.
    Crave JC, Lejeune H, Brebant C, Baret C, Pugeat M. Differential effects of insulin and insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (Hep G2) cells. J Clin Endocrinol Metab 1995;80:1283–1289.PubMedCrossRefGoogle Scholar
  103. 103.
    Pugeat M, Crave JC, Elmidani M, et al. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin. J Steroid Biochem Mol Biol 1991;40:841–849.PubMedCrossRefGoogle Scholar
  104. 104.
    Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr 1987;45:277–282.PubMedGoogle Scholar
  105. 105.
    Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 1993;15:48–65.PubMedGoogle Scholar
  106. 106.
    Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen-and oestrogen-progestin-replacement therapy. Int J Cancer 1999;81:339–344.PubMedCrossRefGoogle Scholar
  107. 107.
    Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000;92:328–332.PubMedCrossRefGoogle Scholar
  108. 108.
    Key TJ. Serum oestradiol and breast cancer risk. Endocr Relat Cancer 1999;6:175–180.PubMedCrossRefGoogle Scholar
  109. 109.
    Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292–1299.PubMedCrossRefGoogle Scholar
  110. 110.
    Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. ‘Hormonal’ risk factors, ‘breast tissue age’ and the age-incidence of breast cancer. Nature 1983;303:767–770.PubMedCrossRefGoogle Scholar
  111. 111.
    Key TJ, Pike MC. The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205–212.PubMedGoogle Scholar
  112. 112.
    Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 1999;10:253–260.PubMedCrossRefGoogle Scholar
  113. 113.
    Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:277–284.PubMedCrossRefGoogle Scholar
  114. 114.
    International Agency for Research and Cancer, Hormonal Contraception and Post-Menopausal Hormonal Therapy. IARC Monographs on the Evaluation of the Carcinogenic Risks to Humans. Lyon, France, 1999.Google Scholar
  115. 115.
    Rutanen EM. Insulin-like growth factors in endometrial function. Gynecol Endocrinol 1998;12:399–406.PubMedCrossRefGoogle Scholar
  116. 116.
    Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127–1135.PubMedCrossRefGoogle Scholar
  117. 117.
    Grady D, Ernster V. Endometrial cancer. In: Schottenfeld D, Fraumeni J, eds. Cancer Epidemiology and Prevention, 2nd ed. Oxford University Press, New York, 1996, pp. 1058–1089.Google Scholar
  118. 118.
    Lukanova A, Lundin E, Micheli A, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004;108:425–432.PubMedCrossRefGoogle Scholar
  119. 119.
    Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90:1774–1786.PubMedCrossRefGoogle Scholar
  120. 120.
    Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996;68:183–223.PubMedGoogle Scholar
  121. 121.
    Wang HS, Chard T. IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. J Endocrinol 1999;161:1–13.PubMedCrossRefGoogle Scholar
  122. 122.
    Rosen CJ. Serum insulin-like growth factors and insulin-like growth factor-binding proteins: clinical implications. Clin Chem 1999;45:1384–1390.PubMedGoogle Scholar
  123. 123.
    Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000;21:215–244.PubMedCrossRefGoogle Scholar
  124. 124.
    Kluge A, Zimmermann R, Munkel B, et al. Insulin-like growth factor I is involved in inflammation linked angiogenic processes after microembolisation in porcine heart. Cardiovasc Res 1995;29:407–415.PubMedCrossRefGoogle Scholar
  125. 125.
    Ma J, Giovannucci E, Pollak M, et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004;96:546–553.PubMedCrossRefGoogle Scholar
  126. 126.
    Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592–1600.PubMedCrossRefGoogle Scholar
  127. 127.
    Palmqvist R, Stattin P, Rinaldi S, et al. Plasma insulin, IGF-binding proteins-1 and-2 and risk of colorectal cancer: a prospective study in northern Sweden. Int J Cancer 2003;107:89–93.PubMedCrossRefGoogle Scholar
  128. 128.
    Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999;91:1147–1154.PubMedCrossRefGoogle Scholar
  129. 129.
    Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004;363:1346–1353.PubMedCrossRefGoogle Scholar
  130. 130.
    Hassink SG, Sheslow DV, de Lancey E, Opentanova I, Considine RV, Caro JF. Serum leptin in children with obesity: relationship to gender and development. Pediatrics 1996;98:201–203.PubMedGoogle Scholar
  131. 131.
    Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996;334:292–295.PubMedCrossRefGoogle Scholar
  132. 132.
    Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998;281:1683–1686.PubMedCrossRefGoogle Scholar
  133. 133.
    Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000:11:327–332.PubMedCrossRefGoogle Scholar
  134. 134.
    Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 2001;121:79–90.PubMedCrossRefGoogle Scholar
  135. 135.
    Attoub S, Noe V, Pirola L, et al. Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, rho-, and rac-dependent signaling pathways. FASEB J 2000;14:2329–2338.PubMedCrossRefGoogle Scholar
  136. 136.
    Stattin P, Palmqvist R, Soderberg S, et al. Plasma leptin and colorectal cancer risk: a prospective study in Northern Sweden. Oncol Rep 2003;10:2015–2021.PubMedGoogle Scholar
  137. 137.
    Stattin P, Lukanova A, Biessy C, et al. Obesity and colon cancer: does leptin provide a link? Int J Cancer 2004;109:149–152.PubMedCrossRefGoogle Scholar
  138. 138.
    Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89:1102–1107.PubMedCrossRefGoogle Scholar
  139. 139.
    Petridou E, Belechri M, Dessypris N, et al. Leptin and body mass index in relation to endometrial cancer risk. Ann Nutr Metab 2002;46:147–151.PubMedCrossRefGoogle Scholar
  140. 140.
    Lagiou P, Signorello LB, Trichopoulos D, Tzonou A, Trichopoulou A, Mantzoros CS. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer 1998;76:25–28.PubMedCrossRefGoogle Scholar
  141. 141.
    Hsing AW, Chua S Jr, Gao YT, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst 2001;93:783–789.PubMedCrossRefGoogle Scholar
  142. 142.
    Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548–2556.PubMedCrossRefGoogle Scholar
  143. 143.
    Gale SM, Castracane VD, Mantzoros CS. Energy homeostasis, obesity and eating disorders: recent advances in endocrinology. J Nutr 2004;134:295–298.PubMedGoogle Scholar
  144. 144.
    Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 2003;9:5699–5704.PubMedGoogle Scholar
  145. 145.
    Dal Maso L, Augustin LS, Karalis A, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004;89:1160–1163.CrossRefGoogle Scholar
  146. 146.
    Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. J Clin Endocrinol Metab 2003;88:993–997.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2006

Authors and Affiliations

  • Susanna C. Larsson
    • 1
  • Hans-Olov Adami
    • 2
  • Alicja Wolk
    • 1
  1. 1.Division of Nutritional Epidemiology, The National Institute of Environmental MedicineKarolinska InstitutetStockholmSweden
  2. 2.Department of Medical Epidemiology and BiostatisticsKarolinska InstitutetStockholmSweden

Personalised recommendations